Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression

Gene Therapy volume 12, pages 1608–1617 (2005)Cite this article

Abstract

We have constructed a novel oncolytic adenovirus (Ad) vector, named VRX-011, in which the replication of the vector is targeted to cancer cells by the replacement of the wild-type Ad E4 promoter with the human telomerase reverse transcriptase (hTERT) promoter. Genes in the Ad E4 transcription unit are essential for Ad replication; therefore, VRX-011 will grow efficiently only in cells in which the hTERT promoter is active, that is, in a wide range of cancer and immortalized cells but not in most somatic cells. Consistent with these expectations, VRX-011 replicated efficiently in all cancer cell lines examined, while its growth was restricted in various primary and normal cells. VRX-011 overexpresses ADP (also known as E3-11.6K), an Ad protein required for efficient cell lysis and release of virions from cells at late stages of infection. This overexpression enhances cell-to-cell spread and could significantly increase antitumor efficacy. In a xenograft model in nude mice, both intratumoral and intravenous administration of VRX-011 effectively suppressed the growth of subcutaneous Hep3B human liver tumors. Also, intravenous delivery of VRX-011 greatly reduced the number and size of A549 human lung cancer cell nodules in a disseminated lung tumor model in nude mice. Importantly, tail vein administration of different doses of VRX-011 in C57BL/6 mice showed minimal liver toxicity. Considering its broad range of lytic replication in cancer cells, its attenuated phenotype in primary cells, its efficacy in suppressing xenografts, and its low toxicity in mouse liver, VRX-011 is a promising candidate for further evaluation as an anticancer therapeutic.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Russell WC . Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573–2604.

    Article  CAS  PubMed  Google Scholar 

  2. Kanerva A, Hemminki A . Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475–480.

    Article  CAS  PubMed  Google Scholar 

  3. Oosterhoff D, Van Beusechem VW . Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004; 4: 37–57.

    CAS  PubMed  Google Scholar 

  4. Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781–787.

    Article  CAS  PubMed  Google Scholar 

  5. Haviv YS, Curiel DT . Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003; 3: 357–385.

    Article  CAS  PubMed  Google Scholar 

  6. Dobbelstein M . Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291–334.

    CAS  PubMed  Google Scholar 

  7. Babiss LE, Friedman JM, Darnell Jr JE . Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 1987; 193: 643–650.

    Article  CAS  PubMed  Google Scholar 

  8. Doronin K et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75: 3314–3324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Toth K et al. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 2004; 64: 3638–3644.

    Article  CAS  PubMed  Google Scholar 

  10. Tauber B, Dobner T . Adenovirus early E4 genes in viral oncogenesis. Oncogene 2001; 20: 7847–7854.

    Article  CAS  PubMed  Google Scholar 

  11. Branton P, Roopchand DE . The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 2001; 20: 7855–7865.

    Article  CAS  PubMed  Google Scholar 

  12. Halbert DN, Cutt JR, Shenk T . Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250–257.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Kim N et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–2015.

    Article  CAS  PubMed  Google Scholar 

  14. Shay JW, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.

    Article  CAS  PubMed  Google Scholar 

  15. Takakura M et al. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558–1561.

    CAS  PubMed  Google Scholar 

  16. Bilsland AE et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370–380.

    Article  CAS  PubMed  Google Scholar 

  17. Gu J et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359–5364.

    CAS  PubMed  Google Scholar 

  18. Gu J et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002; 21: 4757–4764.

    Article  CAS  PubMed  Google Scholar 

  19. Lin T et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620–3625.

    CAS  PubMed  Google Scholar 

  20. Majumdar AS et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy 2001; 8: 568–578.

    Article  CAS  PubMed  Google Scholar 

  21. Takeda T et al. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 2003; 88: 3531–3538.

    Article  CAS  PubMed  Google Scholar 

  22. Huang Q et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 2004; 10: 1439–1445.

    Article  CAS  PubMed  Google Scholar 

  23. Irving J et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004; 11: 174–185.

    Article  CAS  PubMed  Google Scholar 

  24. Kawashima T et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285–292.

    Article  CAS  PubMed  Google Scholar 

  25. Lanson Jr NA et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 2003; 63: 7936–7941.

    CAS  PubMed  Google Scholar 

  26. Wirth T et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63: 3181–3188.

    CAS  PubMed  Google Scholar 

  27. Zou W et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004; 23: 457–464.

    Article  CAS  PubMed  Google Scholar 

  28. Kim E et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415–1428.

    Article  CAS  PubMed  Google Scholar 

  29. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF . New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737–1750.

    Article  CAS  PubMed  Google Scholar 

  30. Ryan PC et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004; 11: 555–569.

    Article  CAS  PubMed  Google Scholar 

  31. Tollefson AE et al. The E3-11.6kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996; 220: 152–162.

    Article  CAS  PubMed  Google Scholar 

  32. Tollefson AE et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296–2306.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Doronin K et al. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378–387.

    Article  CAS  PubMed  Google Scholar 

  34. Krougliak V, Graham FL . Development of cell lines capable of comlementing E1, E4, and protein IX defective adenvorius type 5 mutants. Human Gene Ther 1995; 6: 1575–1586.

    Article  CAS  Google Scholar 

  35. Takakura M et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551–557.

    CAS  PubMed  Google Scholar 

  36. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T . Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 1982; 31: 543–551.

    Article  CAS  PubMed  Google Scholar 

  37. Doronin K et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J Virol 2000; 74: 6147–6155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tollefson AE, Hermiston TW, Wold WSM . Preparation and titration of CsCl-banded adenovirus stocks. In: Wold NJ (ed). Adenovirus Methods and Protocols. The Humana Press, NJ, 1998, pp 1–9.

    Google Scholar 

  39. Kataoka M et al. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 1998; 58: 4761–4765.

    CAS  PubMed  Google Scholar 

  40. Kawakami Y et al. A longer human telomerase reverse transcriptase promoter-based conditionally replicative adenovirus shows oncolysis with less toxicity for ovarian cancer treatment. Mol Ther 2004; 9: S235.

    Google Scholar 

  41. McCormick F . Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2: S157–S160.

    Article  CAS  PubMed  Google Scholar 

  42. Nemunaitis J . Selective replicating viral vectors: potential for use in cancer gene therapy. BioDrugs 2003; 17: 251–262.

    Article  CAS  PubMed  Google Scholar 

  43. Jakubczak JL et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490–1499.

    CAS  PubMed  Google Scholar 

  44. Liu K et al. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147–5152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hiyama K et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711–3715.

    CAS  PubMed  Google Scholar 

  46. Norrback KF, Roos G . Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997; 33: 774–780.

    Article  CAS  PubMed  Google Scholar 

  47. Harle-Bachor C, Boukamp P . Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996; 93: 6476–6481.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yasumoto S et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433–439.

    CAS  PubMed  Google Scholar 

  49. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706–9713.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A . Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567–2583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lichtenstein DL et al. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75–111.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dawn Schwartz for help in preparation of the manuscript. This research was supported by Grants CA81829 and CA71704 to WSMW from the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St Louis, MO, USA

    M Kuppuswamy, J F Spencer, K Doronin, A E Tollefson, W S M Wold & K Toth

Authors
  1. M Kuppuswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J F Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Doronin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A E Tollefson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W S M Wold
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuppuswamy, M., Spencer, J., Doronin, K. et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 12, 1608–1617 (2005). https://doi.org/10.1038/sj.gt.3302581

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302581

Keywords

This article is cited by

Search

Advanced search

Quick links